E-selectin has been established as a mediator of colon and prostate cancer adhesion and distant metastasis (Khatib et al., 2002; Barthel et al., 2007, 2009), and there is clinical and in vitro evidence for the role of E-selectin in promoting metastasis of several other cancers, including breast, pancreatic, and head and neck cancers (Wenzel et al., 1995; Eshel et al., 2000; Barthel et al., 2007; Geng et al., 2012). Here, SELE is linked to prostate carcinoma.